SCHEMBL1883148

SCHEMBL1883148

Cc1ccc2cc(C=O)c(-c3ccccc3C)nc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.56
KDM4E B2RXH2 4/20 0.54
GAA P10253 3/20 0.54
MAPT P10636 5/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
RAB9A P51151 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.43
ESR1 P03372 1/20 0.43
NQO2 P16083 1/20 0.41
CYP1A2 P05177 3/20 0.40
CYP2C19 P33261 2/20 0.40
LMNA P02545 2/20 0.40
HTT P42858 2/20 0.40
CTSD P07339 1/20 0.40
BACE1 P56817 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28736627 0.87 ALDH1A1 (0.49) ALDH1A1KDM4EGAAMAPTSMN1; SMN2
SCHEMBL1882141 0.82 ALDH1A1 (0.61) ALDH1A1KDM4EGAAMAPTSMN1; SMN2
SCHEMBL13647180 0.82 MBNL1 (0.53) ALDH1A1KDM4EGAAMAPTSMN1; SMN2
SCHEMBL4181249 0.77 ATM (0.56) ALDH1A1MAPTRAB9ATSHR
SCHEMBL1877264 0.74 KMT2A (0.43) ALDH1A1KDM4EGAAMAPTSMN1; SMN2
SCHEMBL1888175 0.74 KMT2A (0.43) ALDH1A1KDM4EMAPTSMN1; SMN2RAB9A
SCHEMBL14398982 0.72 ALDH1A1 (0.66) ALDH1A1KDM4EGAAMAPTRAB9A
SCHEMBL1880467 0.72 ALDH1A1 (1.00) ALDH1A1KDM4EGAAMAPTSMN1; SMN2
SCHEMBL30908496 0.72 ALDH1A1 (1.00) ALDH1A1KDM4EGAAMAPTSMN1; SMN2
SCHEMBL1888912 0.72 ALDH1A1 (0.58) ALDH1A1KDM4EGAAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399483-B2 Quinoxaline and quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2013-03-19 US disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed
EP-2231641-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2010-09-29 EP disclosed
WO-2009081105-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE ALDH1A1 4276/4885KDM4E 2230/4885GAA 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.